Login to Your Account

Clinic Roundup

Thursday, August 25, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer demonstrated a 20.7 month median overall survival (OS) in a single-arm Phase II trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription